Altaris Enters into Agreement to Acquire Sharecare

New York, NY – Altaris, LLC (collectively with its affiliates, “Altaris”) announced today that it has entered into a definitive agreement to acquire Sharecare, Inc. (NASDAQ: SHCR) (“Sharecare”) in a take-private transaction for $1.43 per share in cash (the “Transaction”), implying a total equity value of approximately $540 million. Upon consummation of the Transaction, Sharecare will become a privately held company and its common stock will no longer be traded on the NASDAQ.

The Transaction is expected to close during the second half of 2024, subject to certain customary closing conditions, including receipt of approval by Sharecare stockholders and the receipt of required regulatory approvals. Jeff Arnold, the founder of Sharecare, will roll over substantially all of his equity interests in Sharecare as part of the Transaction. Following the closing of the Transaction, Arnold and Brent Layton will continue as Executive Chairman and Chief Executive Officer of Sharecare, respectively.

Sharecare is a digital health company that provides technology and services to stakeholders across the healthcare ecosystem through its three business channels: Enterprise, Provider and Life Sciences. Sharecare’s integrated, data-driven platform engages individuals and helps them manage their care journey with solutions such as benefits navigation, coaching, health information management, and personalized content, enabling consumers, providers, employers, health plans, and government organizations to improve quality of care and drive better outcomes. Sharecare’s platform offerings currently cover 12.4 million lives and over 8,000 hospitals and physician practices.


Houlihan Lokey Capital, Inc. and MTS Health Partners, L.P. are acting as financial advisors to the special committee of Sharecare, and Wachtell, Lipton, Rosen & Katz LLP is acting as legal advisor to the special committee of Sharecare. Kirkland & Ellis LLP is acting as legal advisor to Altaris.

About Altaris

Altaris is an investment firm exclusively focused on the healthcare industry. Altaris seeks to build market-leading companies that deliver innovation and efficiency to the healthcare system, with the ultimate goal of improving access and outcomes for patients. Altaris is headquartered in New York City and manages ~$10 billion of equity capital. For more information, please visit

Important Notice Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “outlook,” “target,” “reflect,” “on track,” “foresees,” “future,” “may,” “deliver,” “will,” “shall,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms, other comparable terminology (although not all forward-looking statements contain these words), or by discussions of strategy, plans, or intentions. These statements involve risks, uncertainties and other factors that are, in many instances, beyond Sharecare’s and Altaris’ control and may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These statements are based on a combination of facts and factors currently known by Sharecare and Altaris and projections of the future, about which we cannot be certain.

Forward-looking statements in this communication include, but are not limited to, statements regarding the proposed transaction, including the benefits of the proposed transaction, the structure of the proposed transaction, the anticipated timing of consummation of the proposed transaction, and plans following the consummation of the proposed transaction. We cannot assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results. Risks and uncertainties include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner, or at all; (ii) the failure to satisfy the conditions to the consummation of the proposed transaction, including, without limitation, the receipt of stockholder and regulatory approvals; (iii) unanticipated difficulties or expenditures relating to the proposed transaction; (iv) the effect of the announcement or pendency of the proposed transaction on Sharecare’s plans, business relationships, operating results and operations; (v) potential difficulties retaining Sharecare employees as a result of the announcement and pendency of the proposed transaction; (vi) the response of Sharecare’s customers, channel partners and suppliers to the announcement of the proposed transaction; (vii) risks related to diverting Sharecare’s management’s attention from its ongoing business operations; and (viii) legal proceedings, including those that may be instituted against Sharecare, its board of directors, its executive officers or others following the announcement of the proposed transaction. Descriptions of some of the other factors that could cause actual results to differ materially from these forward-looking statements are discussed in more detail in Sharecare’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the Risk Factors section of Sharecare’s Annual Report on Form 10-K for the year ended December 31, 2023. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by any person that Sharecare and Altaris will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication speak only as of the date of this communication. Sharecare and Altaris anticipate that subsequent events and developments will cause views to change. However, while Sharecare and Altaris may elect to update these forward-looking statements at some point in the future, Sharecare and Altaris have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of Sharecare and Altaris s of any date subsequent to the date of this communication.

Additional Information and Where to Find It

This communication relates to the proposed transaction involving Sharecare, Inc. (“Sharecare”). In connection with the proposed transaction, Sharecare will file relevant materials with the SEC, including Sharecare’s proxy statement on Schedule 14A (the “Proxy Statement”). This communication is not a substitute for the Proxy Statement or for any other document that Sharecare may file with the SEC and send to its stockholders in connection with the proposed transaction. The proposed transaction will be submitted to Sharecare’s stockholders for their consideration. BEFORE MAKING ANY VOTING DECISION, SHARECARE’S STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Sharecare’s stockholders will be able to obtain a free copy of the Proxy Statement, as well as other filings containing information about Sharecare, without charge, at the SEC’s website ( Copies of the Proxy Statement and the filings with the SEC that will be incorporated by reference therein will also be available, without charge, by directing a request to Sharecare, Inc., 255 East Paces Ferry Road NE, Suite 700, Atlanta, Georgia 30305, Attention: Investor Relations,, or from Sharecare’s website